Your browser doesn't support javascript.
loading
Association between polymorphisms of VKORC1 and CYP2C9 genes with warfarin maintenance dose in a group of warfarin users in Birjand city, Iran.
Fereidouni, Mohammad; Moossavi, Maryam; Kazemi, Touba; Nouranihassankiade, Shaghayeghsadat; Asghari, Arghavan.
Afiliação
  • Fereidouni M; Cellular and Molecular Research Center, Faculty of Medicine, Birjand University of Medical Sciences, Birjand, Iran.
  • Moossavi M; Student Research Committee, Birjand University of Medical Science, Birjand, Iran.
  • Kazemi T; Cardiovascular Diseases Research Center, Professor of cardiology, Birjand University of Medical Sciences, Birjand, Iran.
  • Nouranihassankiade S; Asthma, Allergy, and Immunology Research Center, Faculty of Medicine, Birjand University of Medical Science, Birjand, Iran.
  • Asghari A; Student Research Committee, Birjand University of Medical Science, Birjand, Iran.
J Cell Biochem ; 120(6): 9588-9593, 2019 06.
Article em En | MEDLINE | ID: mdl-30525241
ABSTRACT
Warfarin is the cardinal anticoagulant drug prescribed around the world. Due to stochastic bleeding in patients, it is essential to adjust the dose for every individual. The aim of the present study was to evaluate the frequency of CYP2C9 and VKORC1 gene polymorphisms and their association with warfarin maintenance dose in a sample of cardiovascular patients in Birjand, South-Khorasan province of Iran. Patients with a history of cardiovascular disorders who take warfarin daily were selected. CYP2C9 and VKORC1 gene polymorphisms were detected by polymerase chain reaction-restriction fragment length polymorphism in all participants. A total of 114 patients (mean age 52.7 ± 14.9 years, M/F ratio 0.76) participated in this study. Regarding CYP2C9 gene polymorphisms, the most frequent genotype was 1*/1* (80.4% in females and 62.5% in males). The frequency of 1*/2* and 2*/2* variants was 13% and 6.5% in females and 25% and 12.5% in males, respectively. The frequency of VKORC1 gene (1639 G > A), was 31.5%, 39.5%, and 29% for GG, GA, and AA in males, respectively. Besides, the mentioned genotype frequencies for females were 50%, 40.5%, and 9.5%, respectively. Moreover, there was a statistically significant correlation between VKORC1 gene -1639 G > A variant and warfarin maintenance dose (P < 0.001) but not for CYP2C9 variants. The results of the current study confirmed that the mutant variants of CYP2C9 are not frequent and do not have any impact on warfarin dose. In the case of VKORC1, the mutant allele (A) showed a positive correlation with warfarin dose adjustment.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Varfarina / Polimorfismo de Nucleotídeo Único / Estudos de Associação Genética / Vitamina K Epóxido Redutases / Citocromo P-450 CYP2C9 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Varfarina / Polimorfismo de Nucleotídeo Único / Estudos de Associação Genética / Vitamina K Epóxido Redutases / Citocromo P-450 CYP2C9 Tipo de estudo: Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País/Região como assunto: Asia Idioma: En Ano de publicação: 2019 Tipo de documento: Article